Crescent Biopharma, Inc.
CBIONASDAQHealthcare● Active
$18.15
+$0.87(+5.01%)
Market Cap$500319697
P/E Ratio—
52W High$27.41
52W Low$8.72
Crescent Biopharma, Inc. (CBIO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CBIO · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 29, 2026EPS Actual
-$0.70
Est. -$0.85 · +17.6%
Revenue
$0.00B
Est. $0.00B · +180.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 29, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
CBIO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | -$0.81 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | Apr 29, 2026 | -$0.85 | -$0.70 | +17.6% | $0.00B | $0.00B | +180.0% |
| ▼ Q1 FY2026 | Feb 26, 2026 | -$2.22 | -$4.01 | -80.6% | $0.01B | $0.01B | +8.4% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$1.01 | -$1.27 | -25.7% | — | — | — |
| ▼ Q3 FY2025 | Jul 31, 2025 | -$2.69 | -$4.93 | -83.3% | — | — | — |
| ▲ Q2 FY2025 | May 14, 2025 | -$0.05 | -$0.04 | +20.0% | — | — | — |
| ▲ Q1 FY2025 | Feb 13, 2025 | -$0.16 | -$0.11 | +31.3% | $0.00B | — | — |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$0.11 | -$0.15 | -36.4% | — | — | — |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
-$0.81
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 29, 2026Beat
EPS Actual
-$0.70
EPS Est.
-$0.85
EPS Surpr.
+17.6%
Revenue
$0.00B
Q1 FY2026
Feb 26, 2026Miss
EPS Actual
-$4.01
EPS Est.
-$2.22
EPS Surpr.
-80.6%
Revenue
$0.01B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$1.27
EPS Est.
-$1.01
EPS Surpr.
-25.7%
Revenue
—
Q3 FY2025
Jul 31, 2025Miss
EPS Actual
-$4.93
EPS Est.
-$2.69
EPS Surpr.
-83.3%
Revenue
—
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$0.04
EPS Est.
-$0.05
EPS Surpr.
+20.0%
Revenue
—
Q1 FY2025
Feb 13, 2025Beat
EPS Actual
-$0.11
EPS Est.
-$0.16
EPS Surpr.
+31.3%
Revenue
$0.00B
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$0.15
EPS Est.
-$0.11
EPS Surpr.
-36.4%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-1.01 | $-1.01 | $-1.01 | 2 |
| Q3 FY2027 | $-1.00 | $-1.00 | $-1.00 | 1 |
| Q2 FY2027 | $-0.86 | $-0.86 | $-0.86 | 1 |
| Q1 FY2027 | $-0.80 | $-0.80 | $-0.80 | 2 |
| Q4 FY2026 | $-0.88 | $-0.88 | $-0.88 | 2 |
| Q3 FY2026 | $-0.87 | $-0.82 | $-0.74 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 4 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 4 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 7 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 29, 2026 | +17.6% | $23.96 | $20.94 | -12.60% |
| ▼ Q1 FY2026 | Feb 26, 2026 | -80.6% | $12.49 | $12.35 | -1.12% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -25.7% | $12.43 | $13.10 | +5.39% |
| ▼ Q3 FY2025 | Jul 31, 2025 | -83.3% | $12.60 | $12.42 | -1.43% |
| ▲ Q2 FY2025 | May 14, 2025 | +20.0% | $25.29 | $23.90 | -5.50% |
| ▲ Q1 FY2025 | Feb 13, 2025 | +31.3% | $25.98 | $28.38 | +9.24% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -36.4% | $39.55 | $40.20 | +1.64% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +5.9% | $17.44 | $18.76 | +7.57% |
Q2 FY2026-12.60%
Report Date
Apr 29, 2026
EPS Beat/Miss
+17.6%
Price Before
$23.96
Price After
$20.94
Q1 FY2026-1.12%
Report Date
Feb 26, 2026
EPS Beat/Miss
-80.6%
Price Before
$12.49
Price After
$12.35
Q4 FY2025+5.39%
Report Date
Nov 6, 2025
EPS Beat/Miss
-25.7%
Price Before
$12.43
Price After
$13.10
Q3 FY2025-1.43%
Report Date
Jul 31, 2025
EPS Beat/Miss
-83.3%
Price Before
$12.60
Price After
$12.42
Q2 FY2025-5.50%
Report Date
May 14, 2025
EPS Beat/Miss
+20.0%
Price Before
$25.29
Price After
$23.90
Q1 FY2025+9.24%
Report Date
Feb 13, 2025
EPS Beat/Miss
+31.3%
Price Before
$25.98
Price After
$28.38
Q4 FY2024+1.64%
Report Date
Nov 13, 2024
EPS Beat/Miss
-36.4%
Price Before
$39.55
Price After
$40.20
Q3 FY2024+7.57%
Report Date
Aug 8, 2024
EPS Beat/Miss
+5.9%
Price Before
$17.44
Price After
$18.76
Avg Beat Reaction-0.32%
Avg Miss Reaction+1.12%
Beat Rate4 / 8 quarters
Largest Move-12.60% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CBIO ends December
Crescent Biopharma, Inc. (CBIO) most recently reported earnings on April 29, 2026 for Q2 FY2026, posting EPS of $-0.70 — beating the analyst consensus of $-0.85 by +17.6%. The next CBIO earnings date is expected around September 1, 2026.
Each quarter, investors track CBIO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CBIO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CBIO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CBIO earnings · 5 questionsCrescent Biopharma, Inc.'s next earnings report is expected around September 1, 2026. CBIO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CBIO historically reports after market close (AMC).
CBIO earnings datewhen is CBIO earningsCBIO next earnings datewhen does CBIO report earningsCBIO earnings calendar
▸ Source: FMP · Crescent Biopharma, Inc. SEC filings · US GAAP · Crescent Biopharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026